Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, December 1998, p. 3086-3091, Vol. 42, No. 12
Microbiologie Clinique,
Received 29 January 1998/Returned for modification 13 April
1998/Accepted 22 September 1998
We examined the effectiveness and safety of high-dose oral
co-trimoxazole (trimethoprim-sulfamethoxazole) for the treatment of
orthopedic implants infected with multidrug-resistant
Staphylococcus species. The prospective study was conducted
between 1989 and 1997 in a university medical center with
ambulatory-care services. Patients eligible for the study consisted of
those from whom multidrug-resistant Staphylococcus spp.
organisms susceptible only to glycopeptides and co-trimoxazole were
isolated from their orthopedic implants and for whom there was no
contraindication to the treatment. All patients were treated orally
with high-dose co-trimoxazole (trimethoprim, 20 mg/kg of body
weight/day; sulfamethoxazole, 100 mg/kg/day). Patients with prosthetic
hip infections were treated for 6 months, with removal of any unstable
prosthesis after 5 months of treatment; patients with prosthetic knee
infections were treated for 9 months, with removal of any unstable
prosthesis after 6 months of treatment; and patients with infected
osteosynthetic devices were treated for 6 months, with removal of the
device after 3 months of treatment, if necessary. Monthly clinical
evaluations were conducted until the completion of the treatment, and
follow-up examinations were conducted regularly for up to 6 years. The
overall treatment success rate was 66.7% (26 of 39 patients), with
success rates of 62.5% for patients with prosthetic knee infections,
50% for those with prosthetic hip infections, and 78.9% for those
with other device infections. Seventeen of the 28 (60.7%) patients who
did not have any orthopedic material removed were cured. Eight patients
stopped the treatment because of side effects, and one patient was not compliant. In three patients treatment failed because of the appearance of a resistant bacterium. Long-term oral ambulatory treatment with
co-trimoxazole appears to be an effective alternative to the
conventional medicosurgical treatment of chronic multidrug-resistant Staphylococcus-infected orthopedic implants which includes
long-term intravenous antibiotic therapy combined with surgical
debridement and removal of foreign material or its subsequent one- or
two-stage replacement.
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Ambulatory Treatment of Multidrug-Resistant
Staphylococcus-Infected Orthopedic Implants with High-Dose
Oral Co-trimoxazole (Trimethoprim-Sulfamethoxazole)
*
Corresponding author. Mailing address: Université
de la Méditerranée, Faculté de Médecine,
Unité des Rickettsies, CNRS UPRES-A 6020, 27, boulevard Jean
Moulin, 13385 Marseille Cédex 5, France. Phone: (33)
491.38.55.17. Fax: (33) 491.32.03.90. E-mail: didier.raoult{at}medecine.univ-mrs.fr.
Antimicrobial Agents and Chemotherapy, December 1998, p. 3086-3091, Vol. 42, No. 12
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»